7 results about "NS5A" patented technology

The invention belongs to the field of molecular biological detection, particularly relates to a quantitative composition, a kit, a method and application, and more particularly relates to an HCV quantitative composition, a kit, a method and application. The present invention provides a quantitative composition comprising a homologous vector of at least one portion of at least one of at least one of the 5 'UTR region, CORE region, E1 region, E2 region, P7 region, NS2 region, NS3 region, NS4A region, NS4B region, NS5A region, NS5 region, or 3' UTR region of said HCV, and a quantitative vector, as well as primers and probes for amplifying both vectors. The homologous vector is creatively introduced, and the concentration of the sample to be detected is artificially increased, so that the stability and accuracy of PCR amplification reaction are improved. Particularly, in a sample with low virus load, the HCV can be well detected.

Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and / or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and / or NS5b proteins. In certain embodiments, the subject is a human subject.

This invention discloses a primer set for amplifying a novel HCV subtype 6xp and a primer set for detecting drug resistance mutations. The primer set for amplifying the novel HCV subtype 6xp includes nested PCR primers for amplifying the full length of the novel HCV subtype 6xp, while the primer set for detecting drug resistance mutations is a set of primers targeting drug resistance mutation sites in the three functional regions of NS3, NS5A, and NS5B. The primer set provided by this invention has high specificity and high amplification efficiency, enabling specific amplification of the entire genome of the novel HCV subtype 6xp and accurate detection of drug resistance mutation sites in the three functional regions. It is suitable for clinical diagnosis, antiviral treatment guidance, epidemiological surveys, and viral evolution research of this subtype, and has significant clinical application value and scientific research significance.

The invention discloses an HCV recombinant fusion antigen protein which comprises a Core antigen epitope, an NS3 antigen epitope region and an NS5A antigen epitope of HCV which are connected in series, the amino acid sequence of the Core antigen epitope is as shown in SEQ ID NO: 1, the amino acid sequence of the NS3 antigen epitope is as shown in SEQ ID NO: 2, and the amino acid sequence of the NS5A antigen epitope is as shown in SEQ ID NO: 3. The HCV recombinant fusion antigen protein obtained by the invention has relatively high detection rate and specificity.

Disclosed herein are method of vaccinating or treating a subject for a hepatitis C virus. In certain embodiments, methods comprise administering to a subject a DNA plasmid encoding hepatitis C virus core, E1, E2, and / or p7 proteins. In certain embodiments, methods further comprise administering a recombinant attenuated vaccinia vector encoding hepatitis C virus non-structural NS3, NS4a, NS4b, NS5a and / or NS5b proteins. In certain embodiments, the subject is a human subject.

The present invention provides immunomodulators for enhancing RNA expression, improving RNA stability, and / or prolonging RNA expression time. The invention provides a composition and application thereof. The composition comprises one or more immunomodulatory factors or active variants thereof, wherein the immunomodulatory factors are selected from the group consisting of ORF6, M protein, A46R, SOCS1, SOCS2, SOCS3, NSP5, NS5A, VP35, NS4b, tat, DHX58, B18R, V protein, VP3 and NS1; or a polynucleotide encoding the same; or a vector comprising a polynucleotide encoding the same.

The present disclosure is directed to pharmaceutical formulations comprising an amorphous inhibitor of hepatitis C virus NS5A. These pharmaceutical formulations may be prepared by roller-compaction or wet-granulation methods. The present disclosure is also directed to oral dosage forms, such as tablets, comprising such pharmaceutical formulations.